https://scholars.lib.ntu.edu.tw/handle/123456789/144638
標題: | Ribavirin Enhances Interferon Signaling Via Stimulation of Mtor and P53 Activities | 作者: | SU, WEN-CHENG LIU, WEI-LIANG CHENG, CHING-WEI WU, CHAO-LIANG SHIAU, AI-LI LAI, MING-YANG |
關鍵字: | Ribavirin;mTOR;p53;IFN | 公開日期: | 2009 | 起(迄)頁: | 2793-2798 | 來源出版物: | FEBS Letters | 摘要: | Cellular mechanisms involving the enhancement of interferon( IFN) signaling by ribavirin remain poorly understood. Here, we identified a novel role of ribavirin in the communication between p53 and the mammalian target of rapamycin ( mTOR) signaling. Ribavirin activates p53 by stimulating mTOR and promoting the interaction between mTOR and p53. Activated p 53 stimulates the transcription of IFN regulatory factor 9 and subsequently enhances IFN signaling. Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN- dependent signaling for the IFN- alpha/ribavirin combined treatment. We conclude that ribavirin enhances activities of mTOR and p53, which may account for its antiviral and antitumor effects. Structured summary: MINT- 7222801: mTOR ( uniprotkb: P 42345) physically interacts (MI: 0914) with raptor ( uniprotkb: Q8N122) by anti bait coimmunoprecipitation ( MI: 0006) MINT-7222793: mTOR ( uniprotkb: P42345) physically interacts ( MI: 0914) with RICTOR (uniprotkb : Q8N6M7) by anti bait coimmunoprecipitation ( MI: 0006) MINT-7222784: mTOR ( uniprotkb: P42345) physically interacts ( MI: 0914) with P53 ( uniprotkb: P04637) by anti bait coimmunoprecipitation ( MI : 0006) |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/186665 | DOI: | 10.1016/j.febslet.2009.07.027 | SDG/關鍵字: | alpha interferon; cisplatin; interferon regulatory factor 9; levovirin; mammalian target of rapamycin; protein p53; rapamycin; ribavirin; antineoplastic activity; antiviral activity; apoptosis; article; cell viability; controlled study; cytotoxicity; enzyme activation; growth inhibition; hepatitis C; human; human cell; priority journal; protein protein interaction; signal transduction; upregulation; Animals; Antineoplastic Agents; Antiviral Agents; Cell Line; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Humans; Interferon-alpha; Protein Kinases; Ribavirin; Signal Transduction; Sirolimus; Tumor Suppressor Protein p53; Mammalia; Raptores |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。